



Agile Therapeutics
 Investor Relations Department
 101 Poor Farm Road
 Princeton, NJ 08540
 United States

Visit IR website [↗](#)
 Sign-up for email alerts [↗](#)

| | |
|---------------------|--|
| NASDAQ: AGRX | |
| Last Trade: | 2.78 |
| Trade Time: | 4:00 PM ET Apr 26, 2018 |
| Change: | -0.05 ↓ (-1.767%) |
| Day Range | 2.75 - 2.85 |
| 52-Week Range | 1.93 - 5.60 |
| Volume | 96,614 |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.

Our lead product candidate, Twirla® (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is based on our proprietary transdermal patch technology called Skinfusion® which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability.

Stock Performance



Press Releases [\[View all \]](#)

- Mar 14, 2018*
[Abstract on AG200-15 \(Twirla®\) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition](#)
- Mar 12, 2018*
[Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results](#)
- Dec 22, 2017*
[Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® \(AG200-15\) for the Prevention of Pregnancy](#)
- Nov 6, 2017*
[Agile Therapeutics Reports Third Quarter 2017 Financial Results](#)
- Oct 31, 2017*
[Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine \(ASRM\) Scientific Congress & Expo 2017](#)

Financials [\[View all \]](#)

- Mar 12, 2018*
[Annual Report \(10-K\)](#)
- Apr 25, 2018*
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*
[Quarterly Report \(10-Q\)](#)
- Jul 28, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)